According to a recent LinkedIn post from Quell Therapeutics, the company is highlighting a case study from the U.K. Advanced Therapy Treatment Centre network focused on its CHILL clinical study. The post describes how collaboration with The Newcastle Upon Tyne Hospitals NHS Foundation Trust enabled an expedited study start for this CAR‑Treg advanced therapy investigational medicinal product.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that early, continuous engagement between Quell and the Newcastle site, a dedicated Operational Group for Advanced Therapies, and fully parallel local reviews helped compress site activation timelines. Newcastle reportedly moved the study from Local Information Pack to approval in 36 days, contributing to an overall 113‑day start‑up that is within the U.K. 150‑day target.
For investors, the content suggests Quell is building operational capabilities and partnerships that may reduce time to first‑patient‑in for complex cell therapy trials. Faster and more predictable site start‑up could improve capital efficiency, shorten development timelines, and enhance Quell’s competitive position in the emerging CAR‑Treg and broader cell therapy landscape.
The post also underscores engagement with national research infrastructure, including NIHR Clinical Research Facility, NIHR Industry Hub, Newcastle Advanced Therapies, and Northern Alliance ATTC partners. Such integration with established clinical and translational networks may support scalability of future trials and could strengthen Quell’s attractiveness as a collaborator or partner for larger biopharma companies.